Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2Thoracic 1NET 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 233Lung Neoplasms 96Adenocarcinoma of Lung 39Colorectal Neoplasms 21Adenocarcinoma, Bronchiolo-Alveolar 19Neoplasms 18Small Cell Lung Carcinoma 13Non-Squamous Non-Small Cell Lung Cancer 13Brain Neoplasms 13Neoplasm Metastasis 10Ovarian Neoplasms 9Pleural Effusion, Malignant 8Breast Neoplasms 8Stomach Neoplasms 7Pancreatic Neoplasms 7Meningeal Carcinomatosis 7Mesothelioma 6Melanoma 6Endometrial Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Rectal Neoplasms 4Non-squamous Non-small Cell Lung Cancer 4Carcinoma, Renal Cell 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Non-small Cell Lung Cancer Metastatic 3Mesothelioma, Malignant 3Esophageal Neoplasms 3Colonic Neoplasms 3

Interventions

Trastuzumab 2vatalanib 1tipifarnib 1temsirolimus 1pentetreotide 1Vinorelbine 1Thalidomide 1Sirolimus 1Oxaliplatin 1Leucovorin 1Interleukin-12 Subunit p35 1Interleukin-12 1High-Energy Shock Waves 1Fluorouracil 1Fentanyl 1Everolimus 1Bevacizumab 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Islet Cell × Bevacizumab × Thoracic × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡